The price of Biktarvy can vary significantly depending on factors such as insurance coverage, pharmacy, and geographic location.
What is the typical cash price for Biktarvy?
Without insurance, the retail price for a 30-day supply of Biktarvy can range from approximately $4,000 to over $4,500 [1]. Prices can differ between pharmacies [1].
Are there programs to help with the cost of Biktarvy?
Yes, patients may be eligible for assistance programs. The manufacturer offers a Biktarvy Savings Card that can reduce out-of-pocket costs for eligible commercially insured patients [2]. This program can lower monthly co-pays to as little as $0 for a limited time [2]. For those who are uninsured or underinsured, Gilead, the manufacturer of Biktarvy, offers the Gilead Patient Assistance Program, which provides medication at no cost to eligible individuals [3].
How does insurance affect Biktarvy's cost?
Insurance coverage plays a major role in the patient's out-of-pocket expense. Many insurance plans cover Biktarvy, but co-pays can still apply. These co-pays can range from a few dollars to several hundred dollars per month, depending on the specific insurance plan and formulary [1][2]. Some plans may require prior authorization or step therapy, meaning other medications must be tried first.
When does Biktarvy's patent protection expire?
Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) is protected by multiple patents covering its active ingredients and their formulations [4]. Patent expiry dates for such combination drugs can be complex and may involve different patents expiring at different times. Information on specific patent expiry dates can be found on resources like DrugPatentWatch.com [4].
What are Biktarvy's alternatives and their costs?
There are other HIV medications available, including single-tablet regimens and multi-pill regimens, with varying costs. The cost of alternatives also depends on insurance coverage and manufacturer assistance programs. The choice of treatment is based on individual medical needs and physician recommendation.
Sources:
1. https://www.goodrx.com/biktarvy
2. https://www.biktarvy.com/savings-and-support
3. https://www.gilead.com/patients/patient-assistance
4. https://drugpatentwatch.com/